Loading clinical trials...
Loading clinical trials...
First-in-Human (FIH), Open-Label, Non-Randomized, Single-Arm Phase 1 Study to Evaluate the Safety and Efficacy of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Conditions
Interventions
CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)
Locations
1
China
Beijing Gaobo Boren Hospital
Beijing, Beijing Municipality, China
Start Date
December 13, 2021
Primary Completion Date
December 12, 2023
Completion Date
December 12, 2023
Last Updated
November 14, 2024
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT04628026
NCT06484062
Lead Sponsor
Beijing Boren Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions